WO1992018518A1 - Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same - Google Patents

Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same Download PDF

Info

Publication number
WO1992018518A1
WO1992018518A1 PCT/US1992/003149 US9203149W WO9218518A1 WO 1992018518 A1 WO1992018518 A1 WO 1992018518A1 US 9203149 W US9203149 W US 9203149W WO 9218518 A1 WO9218518 A1 WO 9218518A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
compound
group
base
coupling reagent
Prior art date
Application number
PCT/US1992/003149
Other languages
English (en)
French (fr)
Inventor
Rajender Singh Varma
Michael Edward Hogan
Ganapathi Ramakrishna Revankar
Takkellapati Sudhakar Rao
Original Assignee
Baylor College Of Medicine
Triplex Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine, Triplex Pharmaceutical Corporation filed Critical Baylor College Of Medicine
Publication of WO1992018518A1 publication Critical patent/WO1992018518A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays

Definitions

  • This invention relates to the field of phosphate- free nucleosides and the synthesis of phosphate-free nucleosides which are useful in the formation of oligonucleosides capable of forming a duplex or a triplex with a double stranded DNA.
  • oligonucleotides are used widely as diagnostic reagents and as tools in molecular genetics. More recently "antisense” oligonucleotides have been shown to block the translation and perhaps transcription of genes and are now actively investigated as a new class of pharmaceuticals.
  • the linkage consists of a pair of diastereoisomers which have not been separated. Consequently, an oligomer having n non-ionic internucleotide linkages will consist of a mixture of 2 n isomers.
  • the bridging phosphate group is replaced with other functional groups including carbonate, oxyacetamide, carbamate, silyl and ribonucleoside derived morpholino subunits linked by carbamate groups.
  • these phosphate-free backbones are relatively instable with respect to hydrolysis, are relatively insoluble in water and form duplexes which appear to differ from that of the natural oligonucleotides.
  • the present invention provides an improved method to synthesize chemical compounds capable of forming double helix or triplex-forming oligonucleotides. These chemical compounds exhibit chemical characteristics necessary to form a duplex or triplex, yet replace the phosphodiester linkage of the oligonucleotide backbone.
  • the present invention provides a novel class of compounds capable of entering the cell, resisting nuclease attack and forming stable triplex structures.
  • An object of the present invention is a method for synthesizing novel phosphate-free nucleosides and oligonucleosides capable of forming duplexes or triplexes.
  • An additional object of the present invention is a method for making synthetic nucleosides and oligonucleosides which form duplexes or triplexes with DNA.
  • An additional object of the present invention is a novel synthetic method for forming an oligonucleoside containing a nucleic acid base, sugar and amino acid linker.
  • Another object of the present invention is the formation of a nucleoside and oligonucleoside having an amino acid backbone and capable of forming a duplex or triplex with duplex DNA.
  • a compound for the synthesis of nucleosides containing a nucleo-base, a sugar and an amino acid having the structure
  • R is nucleo-base
  • a further aspect of the present invention is a method of synthesizing compound (I) comprising the steps of oxidizing a 5'-hydroxymethyl functionality of 3'-azido-2',3'-dideoxyribonucleoside or a 3'-azido-3'-deoxyribonucleoside at ambient temperatures in the presence of ruthenium tetroxide.
  • the ruthenium tetroxide is generated in situ by treating RuCl 3 in an aqueous KOH solution with oxidizing agents selected from the group consisting of persulfate and periodates.
  • oxidizing agents selected from the group consisting of persulfate and periodates.
  • oxidizing agents have included to be K 2 S 2 O 8 and NaIO 4 .
  • An additional embodiment of the present invention is an alternate method of synthesizing compound (I) comprising the steps of treating a pyrimidine 2,3' anhydronucleoside with ruthenium tetroxide to form a carboxylic acid derivative and warming the carboxylic derivative with lithium azide in dimethylacetamide.
  • Another aspect of the present invention is a method of synthesizing a nucleoside comprised of a nucleic acid base, a sugar and an amino acid comprising the steps of coupling compound (I) to a benzyl ester of an amino acid in anhydrous dimethylformamide and 1-ethyl-3-[3- (dimethylaminopropyl)]carbodiimide hydrochloride in the presence of triethylamine and subsequent catalytic hydrogenation (Pd/C) of an ethanolic solution of the coupled product.
  • ester of compound (I), the homopolymer of the nucleoside and mixed oligonucleosides of the nucleosides are synthesized.
  • R is a nucleo-base, comprising the steps of catalytic hydrogenation of compound (I), treatment with 9-fluorenylmethyl chloroformate under alkaline conditions and conversion to dithioester with 2,4-bis(ethylthio)-2,4-dithioxocyclo-di- ⁇ 5 -phoesphathiane. Also described are solid phase synthesis procedures for making polymeric nucleosides.
  • the internucleoside backbone linkage includes a D- or L- amino acid.
  • the amino acid is selected from a group consisting of glycine, aspartic acid, glutamic acid, serine, threonine, histidine, arginine, lysine, cysteine, methionine and phosphoserine. In the preferred embodiment, glycine or lysine are used.
  • Figure 1 is a schematic representation showing two alternate synthesis for the nucleoside precusser (I).
  • Figure 2 is a schematic representation of the forming of a nucleoside with amino acid backbone and the formation of an oligonucleoside containing an amino acid backbone.
  • Figure 3 is a schematic representation of the formation of the ester of the compound (I), wherein R' is ethyl.
  • Figures 4 is a schematic representation of a solid phase synthesis of oligonucleosides with an amino acid backbone.
  • Figure 5 is an alternate schematic representation of a solid phase synthesis of oligonucleosides with an amino acid backbone.
  • Figure 6 is a schematic representation of the synthesis of cytidine or adenosine glycine conjugates, monomers and the oligomers.
  • Figure 7 is a schematic representation of the synthesis of guanosine glycine conjugate monomer and oligomers.
  • Figure 8 is a graph showing the thermal denaturization of poly(dA)-poly(T'GLY) as a function of temperature.
  • Figure 9 is a graph showing the thermal denaturization of the poly(dA)-poly(T'GLY) of absorbance at temperatures of 10°C and 85°C.
  • Figure 10 is a schematic representation of the synthesis of an alternate amide-amine linkage.
  • Figure 11 is a representation of different oligonucleosides with an amino acid backbone, e.g. the glycine linkage (39), serine or phosphoserine linkage (40) and arginine or lysine linkage (41).
  • synthetic oligonucleosides as used herein is defined as a molecule comprising two or more deoxyribonucleosides or ribonucleosides preferably more than 10. The exact size will depend on many factors including the specificity and binding affinity.
  • the oligonucleoside will be comprised of a nucleo-base, a sugar and an amino acid.
  • coupling reagent refers to those reagents which are used for coupling in peptide synthesis.
  • Examples of coupling reagents include two types. Those which act by themselves, for example thionyl chloride, triethylamine-borane, or catechol- borane.
  • the second group of coupling reagents work with a helper compound like N-hydroxysuccinimide, N- hydroxysulfosuccinimide, and 1-hydroxybenzotriazole
  • HOBT in N,N-dimethylformamide.
  • Some examples of the coupling reagents in this latter class include dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3- (dimethylamino)propyl]carbodiimide chloride (EDC), Benzotriazole-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), O-Benzotriazol-1-yl-N,N,N',N'-tetramethyl-uronium hexafluoroshosphate (HBTU), O-(N-succinimidyl)-N,N,N',N , -tetramethyluronium tetrafluoroborate (TSTU).
  • DCC dicyclohexylcarbodiimide
  • EDC 1-ethyl-3-[3- (dimethylamino)propyl]carbodi
  • bases when referring to bases herein the term includes both deoxyribonucleic acids and ribonucleic acids.
  • A refers to adenine as well as its derivatives
  • T refers to thymine as well as its derivatives
  • G refers to guanine as well as its derivatives
  • C refers to cytosine as well as its derivatives
  • X refers to xanthine as well as its derivatives
  • I refers to inosine as well as its derivatives.
  • major groove refers to one of the grooves along the outer surface of the DNA helix which is formed because the sugar phosphate backbone of the duplex DNA extends further from the axis than the bases do.
  • the major groove is important for binding of regulator molecules to specific DNA sequences.
  • TFO duplex forming oligonucleoside
  • synthetic oligonucleotides of the present invention which are capable of forming a triplex by binding to the major groove of a duplex DNA structure.
  • duplex forming oligonucleoside refers to synthetic oligonucleosides of the present invention which are capable of forming a duplex by binding to their Watson-Crick complement so as to form an anti-parallel double helix.
  • internucleoside linkage refers to the sugar, amino acid backbone linkage between the bases in the synthetic oligonucleoside. It replaces the internucleotide sugar phosphate linkages found in naturally occurring strands of DNA.
  • the internucleoside backbone linkage includes a D- or L-amino acid.
  • the amino acid is selected from the group consisting of glycine, aspartic acid, glutamic acid, serine, threonine, histidine, arginine, lysine, cysteine, methionine and phosphoserine.
  • the oligonucleoside backbone must provide sufficient conformational freedom to allow for base pairing and base overlap. In the naturally occurring phosphodiester backbone there is substantial conformational freedom in the duplex as determined by crystallographic order parameters, dynamics analysis and binding of intercalators. This conformational freedom is limited but finite. Thus, the alternative nucleoside linkage must provide for conformational flexibility similar to the five rotatable bonds which comprise the linkage between C-4' and C-3" in a duplex. The molecules of the present invention have about 5 to 7 rotatable bonds in the backbone linkage.
  • the charge is important. From a thermodynamic perspective, the anionic nature of the phosphodiester is intrinsically unfavorable. Upon duplex or triplex formation the anionic nature results in a very high local charge density in a duplex or triplex. Consequently, duplex or triplex formation is greatly destabilized in the absence of monovalent or divalent counterions. These counterions are consumed upon duplex or triplex formation and serve to shield closely spaced negative charge.
  • a positive charged or neutral backbone is used.
  • phosphodiester linkage Another important aspect of the phosphodiester linkage is the hydration.
  • macromolecules fold in aqueous solution so as to isolate water insoluble substituents from solution contact while presenting well hydrated substituents near the surface area in contact with water.
  • This general principal is well known for protein folding, and is of equal importance to understanding a nucleic acid structure.
  • deoxyribonucleosides become relatively water insoluble.
  • This situation also pertains to oligonucleotides. Therefore, not surprisingly, DNA structures fold to minimize hydration of the nucleoside moiety and tend to form stacked arrays which minimize base contact with water.
  • the nucleoside moiety provides tight surface binding of 6-8 H 2 O molecules and weaker binding of 10-15 H 2 O equivalents per nucleoside. This binding is principally in the major and minor grooves.
  • the internucleoside linkage of the present invention is strongly hydrated to present a hydrophilic face to aqueous solution.
  • the oligonucleosides of the present invention are designed to be used for duplex forming (antisense) or triplex-forming pharmaceuticals.
  • the internucleoside linkage must be stable with respect to general base catalysis and enzyme catalyzed hydrolysis in serum or cells.
  • novel nucleosides of the present invention are their ability to be adaptable to solid phase synthetic methods.
  • the ability of the synthetic chemistry to be adapted to the solid phase synthetic methods facilitates the rapid production of the compounds.
  • one embodiment of the present invention includes as a composition of matter an oligonucleoside characterized as having a phosphate-free internucleoside backbone linkage; having about 5 to 7 rotatable bonds in said backbone linkage having a strongly hydrated internucleoside linkage presenting a hydrophilic face to aqueous solution; and capable of forming double or triple helices.
  • this composition of matter can be further characterized as having a positive charged or a neutral backbone.
  • the oligonucleoside is further characterized as having considerable stability to general base catalysis or enzyme hydrolysis in body tissue.
  • the internucleoside backbone linkage includes a D- or L-amino acid.
  • the amino acid is usually selected from the group consisting of glycine, aspartic acid, glutamic acid, serine, threonine, histidine, arginine, lysine, cysteine, methionine and phosphoserine.
  • the amino acid is glycine or lysine.
  • Another embodiment of the present invention includes a compound for the synthesis of nucleosides containing a nucleo-base, a sugar and an amino acid said compound having the structure:
  • R is a nucleo-base
  • a further embodiment includes a method of synthesizing compound (I) comprising the step of oxidizing a 5'-hydroxymethyl functionality of a 3'-azido, 2',3'-dideoxynucleoside or a 3'-azido-3'-deoxynucleoside at ambient temperature in the presence of ruthenium tetroxide. (see Figure 1).
  • the ruthenium tetroxide can be generated in situ by treating RuCl 3 in an aqueous KOH solution with oxidizing agents selected from the group consisting of persulfate and periodates.
  • the oxidizing agents are either K 2 S 2 O 8 or NaIO 4 .
  • An alternate method of synthesizing compound (I) comprises the steps of treating a pyrimidine 2,3'-anhydronucleoside with ruthenium tetroxide to form a carboxylic acid derivative and warming the carboxylic derivative with lithium azide and dimethylacetamide. (see Figure 1).
  • a further embodiment of the present invention is a method of synthesizing a nucleoside comprising a nucleo-base, a sugar and an amino acid by the steps of coupling compound (I) to a benzyl ester of an amino acid with a coupling reagent (for example, anhydrous dimethylformamide and 1-ethyl-3-[3- (dimethylaminopropyl)]carbodiimide hydrochloride in the presence of triethylamine) and subsequent catalytic hydrogenation (Pd/C) of an ethanolic solution of the coupled product. (see Figure 2).
  • a coupling reagent for example, anhydrous dimethylformamide and 1-ethyl-3-[3- (dimethylaminopropyl)]carbodiimide hydrochloride in the presence of triethylamine
  • Pd/C catalytic hydrogenation
  • a compound selected from the group consisting of 1-hydroxybenzotriazole, N- hydroxysuccinimide and N-hydroxysulfosuccinimide can be added.
  • a polymer of the synthesized monomer nucleosides can be made by the steps of coupling the monomers to each other in anhydrous N,N-dimethylformamide with a coupling reagent (for example, dicyclohexylcarbodiimide) and a compound selected from the group consisting of 1- hydroxybenzotriazole, N-hydroxysuccinimide and N-hydroxysulfosuccinimide.
  • a further improvement of this synthetic method is the addition of a step to remove the solvent and adding methanol to precipitate a water soluble polymer. This polymer can be used as a TFO or a DFO.
  • nucleoside carboxylic acids can be used in the above described nucleoside synthesis method.
  • Figure 2 the synthesis of thymidine conjugate is shown.
  • the benzyl ester of an amino acid with appropriate amino acid side chain protection was selected from the group consisting of serine benzyl ester, ⁇ -acetyl lysine benzyl ester, glycine benzyl ester, threonine benzyl ester, aspartate benzyl ester, glutamate benzyl ester, histidine benzyl ester, methionine benzyl ester, cysteine benzyl ester and arginine benzyl ester.
  • nucleo-base in the nucleoside synthesis method is adenine, cytosine or guanine
  • a further step enhanced the reaction, (see Figures 6 and 7).
  • the carboxylic functionality Prior to the coupling step there is sequential protection first of the carboxylic functionality with t-butyldimethylsilyl and then the amine functionality with isobutyrylchloride or benzoyl chloride. The carboxylic functionality is then selectively deprotected with fluoride ion and the method proceeds as described above.
  • the homopolymer of the nucleoside can be synthesized by coupling the synthesized monomers to each other with a coupling reagent (for example, dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in anhydrous N,N-dimethylformamide) and deprotecting the polymer thus formed (see Figures 2, 6 and 7).
  • a coupling reagent for example, dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in anhydrous N,N-dimethylformamide
  • a further aspect of the present invention is the preparation of a compound of the structure:
  • R is a nucleo-base.
  • the method comprises the steps of esterification of compound (I) with ethanol in the presence of dicyclohexylcarbodiimide and 4-dimethylaminopyridine (DMAP) or with ethanolic HCl in triethyl orthoformate. (see Figure 3).
  • a further procedure is a method of synthesizing a dithioester of the formula:
  • R as a nucleo-base.
  • This compound can be synthesized by the steps of catalytic hydrogenation of compound (I) with Pd/C, treatment with 9-fluorenylmethyl chloroformate under alkaline conditions to give compound (11) which is further converted to the dithioester (10) with 2,4-bis(ethylthio)-2,4- dithioxocyclo-di- ⁇ 5 -phosphathiane (see Figure 4).
  • the reactions are carried out by solid phase synthesis of the polymeric nucleoside.
  • Each nucleoside contains a nucleo-base, a sugar moiety and an amino acid backbone.
  • the first step is the linkage of compound (I) to a solid phase support, followed by the synthetic procedures described above and shown in Figures 2-4 and 6, 7 and 10.
  • a further enhancement is the coupling of the solid phase compound with 9-fluorenylmethyl (Fmoc) amino acid, then deprotecting the amine functionality with piperidine, coupling a monomer nucleoside in the presence of a coupling reagent (for example, dicyclohexylcarbodiimide and 1-hydroxybenzotriazole) and repeating the 9-fluorenylmethyl amino acid coupling, piperidine deprotection and addition of monomer steps until a polymer of sufficient size has been synthesized. The polymer is then removed from the solid phase support ( Figures 4 and 5). In another embodiment an oligonucleoside (13) with an. amino acid linkage containing sulfur is synthesized.
  • a coupling reagent for example, dicyclohexylcarbodiimide and 1-hydroxybenzotriazole
  • R is a nucleo-base; chlorination of the hydroxymethyl function with hexamethylphosphoramidethionyl chloride reagent; and base catalyzed condensation with:
  • An additional carbon unit can be introduced into the amino acid linkage by oxidation of 5'-cyano-3'-azido-3',5'-dideoxythymidine (VI) under basic conditions. This general procedure is applicable to other nucleo bases.
  • the present invention is designed to generate amine and carboxylic acid functionalities on the carbohydrate moiety of the nucleoside monomer at 3'- and 4'- positions, respectively.
  • An example of the approach for thymine is seen in Figure 1.
  • Synthesis of the thymine derivative (2) of (I) was achieved in an efficient manner by the oxidation of commercially available 3'-azido-3'- deoxythymidine (1).
  • a novel feature of the present invention using ruthenium tetroxide is its applicability to pyrimidine nucleosides where ring opened side products are generally formed during the traditional oxidation methods. Using the procedure of the present invention, formation of such side products have not been observed after using a variety of 2',3'-isopropylidene purine and pyrimidine nucleosides. Since thymidine is the most sensitive base to such oxidative ring opening, the generality of the present invention was confirmed by using thymidine as the substrate for oxidation activation ( Figure 1).
  • Compound (8) was obtained from 10 g of Compound (2) via esterification with 20 ml of ethanol in the presence of DCC/DMAP. This is a valuable precursor with a blocked carboxylic acid end for further elaboration at the 3'-amino functionality.
  • Figure 4 shows the coupling of (9) with Fmoc-glycine in the presence of EDC/HOBT yields 1-(3-glycineamido-2,3-dideoxy- ⁇ -D-erythro-pentofuranosyl-5-uronic acid) thymine (12).
  • compound (12) with piperidine and subsequent reaction with compound (11) yields the dimer (14).
  • the target oligonucleoside with amino acid backbone can be synthesized using nucleoside-amino acid conjugate by a standard solid phase methodology ( Figure 5).
  • Thymidine derivative The 3'-azido nucleosides are synthesized in large scale for use in the amide coupling procedure.
  • (1) is synthesized as described in Figure 1, in high yield by employing a known procedure via the intermediate 2,3'-anhydrothymidine (3).
  • compound (3) is prepared using relatively inexpensive thymidine and diphenyl sulfite. Rao & Reese, J. Chem. Soc, Chem. Comm. 997 (1989).
  • Upon warming the acid (4) with 2 molar equivalents of lithium azide in dimethylacetamide solution yields (2) in gram quantities.
  • 3.5 g of (2) was synthesized. This provides an efficient and relatively inexpensive method for monomer synthesis.
  • Cytidine. adenosine and ⁇ uanosine derivatives The synthesis of the amino acid-nucleoside monomers containing 2'-deoxycytidine, 2'-deoxyadenosine and 2'- deoxyguanosine are prepared from the corresponding 3'- azido derivatives by oxidizing the 5'-hydroxymethylene functionality.
  • the starting material 3'-azido-2',3'- dideoxycytidine (19a) or 3'-azido-2',3'-dideoxyadenosine (19b) were synthesized in gram quantities employing known methods, for example see, Lin and coworkers, J. Med. Chem. 26:1691 (1983).
  • the polymerization of the T'gly monomer (6) was accomplished using the standard DDC coupling reaction in the presence of HOBT. A 10 fold excess of the DDC and HOBT are employed in anhydrous DMF with monomer concentration of lOmg/ml. Removal of the solvent and addition of methanol precipitated the polymer. The precipitated polymer dissolved readily in water at a solubility limit near to lmg/ml at pH 7, room temperature (approximately 5mgs/ml at pH 9.5).
  • the resulting distribution from polymer synthesis can be fractionated employing NACS ion-exchange HPLC, and using an ammonium acetate gradient.
  • the size of the resulting (T'gly) n oligomers was estimated by quantitative labeling of the amino terminus with malachite green isothiocyanate, then comparison of the absorbance of the resulting conjugates at 270nm vs 620nm. Based upon this analysis, the above described polymerization reaction results in an average chain length of 20 bases.
  • T'gly polymers are capable of duplex formation with a standard phosphodiester complement
  • a mixing analysis was performed. Increasing concentration of (T'gly) n was added to high molecular weight polydA. The resulting change of UV absorbance properties was monitored. The T'gly polymer was fractionated by pressure filtration on a centricon membrane with 10,000 MW cutoff to yield a heterogeneous polymer population with length greater than about 30 bases.
  • a 1/1 polydA-(T'gly) 30 complex displays 50% thermal hyperchromism, with an apparent Tm of 55°, in 0.5M NaCl, 10mM Tris/HCl pH 7.6,
  • nucleoside-amino acid monomers glycine, serine, phosphoserine, lysine and arginine
  • the power of the invention described herein is that the physical properties of the oligonucleoside-amino acid co-polymer can be altered by amino acid substitution, while keeping the basic synthetic chemistry the same.
  • Serine and Phosphoserine Serine linked homopolymers (40) ( Figure 11) are synthesized as described for the corresponding glycinates, by condensation with the corresponding serine benzyl ester.
  • the phosphoserine (40) linked oligonucleosides are prepared from the corresponding serine linked oligomers by direct post-synthetic phosphorylation with POCl 3 in trimethyl phosphate or in aqueous pyridine. The extent of phosphate modification is confirmed by elemental analysis and 31 P NMR.
  • Lysine The lysine linked oligomers, (41) ( Figure 11) is synthesized from the ⁇ -acetyl lysine benzyl ester which is commonly used for standard Fmoc polypeptide synthesis.
  • the acetyl blocking group is removable in 9M NH 4 OH (concomitant with base deblocking) and remains stable during the carbodiimide coupling steps required for the solution phase homopolymer synthesis.
  • 9M NH 4 OH concomitant with base deblocking
  • the more stable ⁇ -benzoyl amine modification may be required. Such protection is reminiscent of the procedure used for the base amines and can be removed by hydrolysis in ammonia.
  • Arginine The Arginine linked oligomers, (41) ( Figure 11) is synthesized from the ⁇ -acetyl lysine benzyl ester which is commonly used for standard Fmoc polypeptide synthesis.
  • the acetyl blocking group is removable in
  • the arginine linked oligomers, (41) ( Figure 11) is synthesized from the corresponding arginine benzyl ester. Because of the pK a difference, guanidinium blocking is not required for the synthesis of homopolymers. For solid phase methods, however, the guanidinium group is protected with a nitro group. This nitro group is removable after polymerization by catalytic hydrogenation.
  • Thymidine was prepared as described above ( Figure 2, compound 5).
  • the corresponding benzyl esters of serine, ⁇ -acetyl lysine and arginine are prepared and coupled by the same procedure.
  • the desired monomer 1-(3-amino-2,3-dideoxy- ⁇ -D-erythro ⁇ pentofuranosyl-5-glycine uronate)-N 4 -benzoylcytosine (23a) is produced.
  • This compound (23a) can be polymerized by the carbodiimide chemistry as shown in Figure 6.
  • the average chain length of (T'gly) n oligomers can be estimated by end group determination. Size is also assayed by analytical molecular sieve chromatography.
  • the co-polymers are similar to polypeptides in terms of water solubility and chain dynamics. Thus, for chain lengths greater than 20, the co-polymers can be analyzed by SDS polyacrylamide electrophoresis, visualizing with silver stain or by radiochemical end labelling with a primary amine specific reagent. For polymers with charged backbones or for those with T or G above pH 10, polyacrylamide electrophoresis can also be performed without SDS.
  • the selectivity and thermodynamic stability of duplexes and triplexes containing nucleo-base-amino acid copolymers are assessed by a band shift method, by UV detected melting and by footprinting methods.
  • thermodynamics of the duplex to strands and triplex to duplex + strand equilibrium is assessed by observing the characteristic absorbance or ellipticity change attendant to the melting transition. Interpretation of such data is well understood in the art to assess thermodynamic parameters
  • nucleo base-amino acid copolymers were modified at the N terminus with photochemicals or with DTPA to generate a site for iron chelation and subsequent Fenton chemistry. These two methods were used to confirm the preferred strand orientation in duplexes and triplexes. Eosin can be used as the photochemical, because it binds weakly to DNA on its own.
  • the activated amine modifier DTPA was chosen as a selective chelator for the Fenton reaction because of its amine chemistry and capacity to chelate iron.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Saccharide Compounds (AREA)
PCT/US1992/003149 1991-04-19 1992-04-16 Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same WO1992018518A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/687,807 US5175266A (en) 1991-04-19 1991-04-19 Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same
US687,807 1991-04-19

Publications (1)

Publication Number Publication Date
WO1992018518A1 true WO1992018518A1 (en) 1992-10-29

Family

ID=24761935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/003149 WO1992018518A1 (en) 1991-04-19 1992-04-16 Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same

Country Status (3)

Country Link
US (1) US5175266A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0565646A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1992018518A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5623049A (en) * 1993-09-13 1997-04-22 Bayer Aktiengesellschaft Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics
US5955571A (en) * 1994-08-08 1999-09-21 Bayer Aktiengesellschaft Nucleic acid-binding oligomers for therapy and diagnosis

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403302B1 (en) 1992-09-17 2002-06-11 California Institute Of Technology Methods and compositions for triple helix formation
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
US6331617B1 (en) 1996-03-21 2001-12-18 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US5734040A (en) * 1996-03-21 1998-03-31 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US6274313B1 (en) 1996-03-21 2001-08-14 Pioneer-Hybrid International, Inc. Oligonucleotides with cationic phosphoramidate internucleoside linkages and methods of use
KR100408414B1 (ko) * 2001-06-20 2003-12-06 삼성전자주식회사 반도체 소자 및 그 제조방법
US20040106785A1 (en) * 2002-07-25 2004-06-03 Micrologix Biotech Inc. Inhibitors of RNA dependent RNA polymerase and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483964A (en) * 1983-06-20 1984-11-20 Chiron Corporation Reactor system and method for polynucleotide synthesis
US4517338A (en) * 1983-06-20 1985-05-14 Chiron Corporation Multiple reactor system and method for polynucleotide synthesis
US4591614A (en) * 1983-10-07 1986-05-27 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
US4625065A (en) * 1983-07-01 1986-11-25 Stauffer Chemical Company Process for preparation of trimethylsulfoxonium salts
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4736036A (en) * 1983-08-08 1988-04-05 Appleton Papers Inc. Process for the preparation of quinolinic acid
US4889952A (en) * 1987-03-12 1989-12-26 Nippon Petrochemical Company, Ltd. (Phenylethenyl) phenylpropionaldehyde and method for producing (benzolyphenyl) propionic acid using the same
US4950745A (en) * 1986-10-30 1990-08-21 Daicel Chemical Industries, Ltd. Process for synthesis of oligonucleotides and compound for forming polymeric protecting group
US5053454A (en) * 1989-02-15 1991-10-01 Sri International Multiple polymer synthesizer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479942A (en) * 1981-08-10 1984-10-30 Fujisawa Pharmaceutical Co., Ltd. Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof
JPS5998099A (ja) * 1982-11-05 1984-06-06 Fujisawa Pharmaceut Co Ltd 新規テトラヒドロフランカルボン酸誘導体、その製造法およびその医薬組成物
EP0639582B1 (en) * 1985-03-15 1998-09-16 Antivirals Inc. Polynucleotide assay reagent and method

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483964A (en) * 1983-06-20 1984-11-20 Chiron Corporation Reactor system and method for polynucleotide synthesis
US4517338A (en) * 1983-06-20 1985-05-14 Chiron Corporation Multiple reactor system and method for polynucleotide synthesis
US4625065A (en) * 1983-07-01 1986-11-25 Stauffer Chemical Company Process for preparation of trimethylsulfoxonium salts
US4736036A (en) * 1983-08-08 1988-04-05 Appleton Papers Inc. Process for the preparation of quinolinic acid
US4591614A (en) * 1983-10-07 1986-05-27 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4950745A (en) * 1986-10-30 1990-08-21 Daicel Chemical Industries, Ltd. Process for synthesis of oligonucleotides and compound for forming polymeric protecting group
US4889952A (en) * 1987-03-12 1989-12-26 Nippon Petrochemical Company, Ltd. (Phenylethenyl) phenylpropionaldehyde and method for producing (benzolyphenyl) propionic acid using the same
US5053454A (en) * 1989-02-15 1991-10-01 Sri International Multiple polymer synthesizer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0565646A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5623049A (en) * 1993-09-13 1997-04-22 Bayer Aktiengesellschaft Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics
US5955571A (en) * 1994-08-08 1999-09-21 Bayer Aktiengesellschaft Nucleic acid-binding oligomers for therapy and diagnosis

Also Published As

Publication number Publication date
EP0565646A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-08-03
US5175266A (en) 1992-12-29
EP0565646A1 (en) 1993-10-20

Similar Documents

Publication Publication Date Title
KR100225090B1 (ko) 이중가닥 핵산을 위한 서열특이적 결합 중합체
JP2670434B2 (ja) ポリヌクレオチド測定試薬と方法
JP4948690B2 (ja) 共有結合したオリゴヌクレオチド小溝結合物質複合体
EP1954671B1 (en) Polynucleotide labelling reagent
EP0135587B2 (en) Defined sequence single strand oligonucleotides incorporating reporter groups, process for the chemical synthesis thereof, and nucleosides useful in such synthesis
JP4791043B2 (ja) 同一固体支持体上で、２以上のオリゴヌクレオチドをタンデムに合成するための方法および組成物
Ono et al. Triplex formation of an oligonucleotide containing 2'-O-methylpseudoisocytidine with a DNA duplex at neutral pH
US20020068708A1 (en) Oligonucleotide analogues
IL185570A (en) Cyclic acid and analogues of nucleotide nucleotides and oligonucleotides
JPH07505903A (ja) オリゴヌクレオチド合成に有用な保護基
AU6897196A (en) Cationic oligonucleotides, and related methods of synthesis and use
US5175266A (en) Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same
PT1276760E (pt) Derivados de ácido poliamida-nucleico, agentes e processos para a sua preparação
De Napoli et al. A new solid-phase synthesis of oligonucleotides 3′-conjugated with peptides
US20030129593A1 (en) Process for producing multiple oligonucleotides on a solid support
Capasso et al. Solid phase synthesis of DNA-3′-PNA chimeras by using Bhoc/Fmoc PNA monomers
Govindaraju et al. Backbone extended pyrrolidine PNA (bepPNA): A chiral PNA for selective RNA recognition
US6136965A (en) Deoxynucleic alkyl and alkoxy thiourea compounds
EP0458876A1 (en) Method of separating oligonucleotides from a mixture.
WO1995029184A1 (fr) Bases nucleiques polycationiques et oligonucleotides les contenant
US6872809B2 (en) Nucleoside derivatives
Antsypovich et al. Synthesis of modified oligonucleotides and production of duplexes with covalently linked chains
RU2787350C1 (ru) Способ получения морфолиновых олигомеров
Neuner New non nucleosidic phosphoramidite reagent for solid phase synthesis of biotinylated oligonucleotides
US7442788B2 (en) Antisense molecules and method of controlling expression of gene function by using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 1992910913

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992910913

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1992910913

Country of ref document: EP